Skip to content
Boca Raton City Online – Lifestyle
Author:
Propanc Biopharma, Inc.
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
August 18, 2026
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
August 12, 2026
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
August 6, 2026
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
August 5, 2026
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
July 21, 2026
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
July 7, 2026
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
July 2, 2026
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
June 16, 2026
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
June 11, 2026
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
June 2, 2026
1
2
Next Page
→